SIMCERE PHARMA (02096) Income Statement & Earnings

11.380
-0.230-1.98%

Market Closed May 15 16:07 CST

29.54BMarket Cap19.86P/E (TTM)

SIMCERE PHARMA (02096) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q6)Jun 30, 2025

(FY)Dec 31, 2024

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

Turnover

16.52%7.73B

15.14%3.58B

0.41%6.64B

-7.93%3.11B

4.49%6.61B

25.26%3.38B

26.49%6.32B

27.34%2.7B

10.89%5B

10.11%2.12B

Operating income

16.52%7.73B

15.14%3.58B

0.41%6.64B

-7.93%3.11B

4.49%6.61B

25.26%3.38B

26.49%6.32B

27.34%2.7B

10.89%5B

10.11%2.12B

Cost of sales

-8.46%-1.42B

-6.06%-691.06M

19.28%-1.31B

20.57%-651.59M

-22.32%-1.62B

-47.18%-820.36M

-22.91%-1.33B

-21.97%-557.37M

-20.01%-1.08B

-17.74%-456.98M

Operating expenses

-8.46%-1.42B

-6.06%-691.06M

19.28%-1.31B

20.57%-651.59M

-22.32%-1.62B

-47.18%-820.36M

-22.91%-1.33B

-21.97%-557.37M

-20.01%-1.08B

-17.74%-456.98M

Gross profit

18.50%6.31B

17.54%2.89B

6.83%5.32B

-3.88%2.46B

-0.25%4.98B

19.56%2.56B

27.47%5B

28.82%2.14B

8.62%3.92B

8.18%1.66B

Selling expenses

-16.07%-2.91B

-16.87%-1.35B

-6.56%-2.51B

7.36%-1.16B

1.93%-2.36B

-21.19%-1.25B

-17.97%-2.4B

-23.99%-1.03B

-29.70%-2.04B

-32.09%-830.18M

Administrative expenses

-13.14%-599.3M

-14.46%-264.19M

-6.09%-529.69M

10.36%-230.81M

-11.93%-499.28M

-36.60%-257.47M

-21.66%-446.08M

-15.29%-188.48M

10.89%-366.66M

15.50%-163.48M

Research and development expenses

-10.28%-1.56B

-11.71%-632.42M

9.33%-1.42B

27.04%-566.13M

9.56%-1.56B

-19.09%-775.89M

-21.99%-1.73B

-3.95%-651.54M

-24.06%-1.42B

-38.03%-626.8M

Impairment and provision

-57.37%2.92M

-145.32%-827K

689.16%6.84M

94.36%1.83M

-93.79%867K

-95.31%939K

188.27%13.97M

150.54%20.03M

---15.83M

---39.63M

-Other impairment is provision

-57.37%2.92M

-145.32%-827K

689.16%6.84M

94.36%1.83M

-93.79%867K

-95.31%939K

188.27%13.97M

150.54%20.03M

---15.83M

---39.63M

Special items of operating profit

966.20%319.51M

303.65%38.78M

-125.34%-36.89M

-100.94%-19.04M

-65.91%145.59M

905.89%2.03B

-68.71%427.08M

-145.53%-251.85M

208.84%1.36B

1,410.37%553.17M

Operating profit

85.95%1.56B

39.11%684.65M

17.52%836.49M

-78.70%492.16M

-17.29%711.8M

5,521.48%2.31B

-40.59%860.61M

-92.61%41.11M

56.29%1.45B

86.71%556.11M

Financing income

40.72%55.75M

4.47%26.55M

-27.91%39.62M

-17.86%25.41M

-8.20%54.96M

2.23%30.94M

-12.33%59.87M

8.02%30.26M

160.16%68.29M

158.17%28.01M

Financing cost

-37.73%-95.8M

-106.81%-48.54M

-101.22%-69.56M

-29.26%-23.47M

-0.47%-34.57M

1.93%-18.16M

51.43%-34.41M

60.94%-18.51M

47.02%-70.85M

40.44%-47.4M

Share of profits of associates

-66.42%-2.72M

-10,700.00%-1.91M

-128.03%-1.63M

102.27%18K

4,963.48%5.82M

-104.91%-793K

100.26%115K

97.38%-387K

-216.53%-43.92M

-238.85%-14.75M

Share of profit from joint venture company

-57.67%1.61M

202.79%1.74M

87.73%3.79M

-51.69%573K

2,594.67%2.02M

2,137.74%1.19M

127.78%75K

139.55%53K

31.30%-270K

-235.00%-134K

Earning before tax

87.25%1.51B

33.92%662.49M

9.28%808.72M

-78.72%494.69M

-16.50%740.04M

4,325.15%2.32B

-36.78%886.25M

-89.94%52.52M

74.12%1.4B

132.20%521.84M

Tax

-96.42%-170.32M

-54.56%-58.88M

-232.39%-86.71M

25.81%-38.09M

-164.45%-26.09M

-646.35%-51.35M

-58.32%40.48M

-71.57%9.4M

168.98%97.12M

182.85%33.06M

After-tax profit from continuing operations

86.15%1.34B

32.20%603.61M

1.13%722M

-79.91%456.6M

-22.96%713.95M

3,570.60%2.27B

-38.17%926.73M

-88.84%61.92M

125.64%1.5B

200.21%554.9M

Earning after tax

86.15%1.34B

32.20%603.61M

1.13%722M

-79.91%456.6M

-22.96%713.95M

3,570.60%2.27B

-38.17%926.73M

-88.84%61.92M

125.64%1.5B

200.21%554.9M

Minority profit

----

80.39%-811K

56.47%-811K

49.41%-4.14M

36.18%-1.86M

-55.80%-8.18M

-327.38%-2.92M

Profit attributable to shareholders

86.15%1.34B

32.20%603.61M

1.01%722M

-79.92%456.6M

-23.22%714.76M

3,464.66%2.27B

-38.23%930.87M

-88.57%63.78M

125.10%1.51B

200.68%557.81M

Basic earnings per share

86.21%0.54

38.89%0.25

7.41%0.29

-79.31%0.18

-25.00%0.27

4,250.00%0.87

-37.93%0.36

-90.48%0.02

107.14%0.58

162.50%0.21

Diluted earnings per share

86.21%0.54

38.89%0.25

7.41%0.29

-79.07%0.18

-25.00%0.27

4,200.00%0.86

-37.93%0.36

-90.48%0.02

107.14%0.58

162.50%0.21

Currency Unit

CNY

Accounting Standards

HKAS

Audit Opinions

Unqualified Opinion

Auditor

KPMG

	(FY)Dec 31, 2025	(Q6)Jun 30, 2025	(FY)Dec 31, 2024	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021
Turnover	16.52%7.73B	15.14%3.58B	0.41%6.64B	-7.93%3.11B	4.49%6.61B	25.26%3.38B	26.49%6.32B	27.34%2.7B	10.89%5B	10.11%2.12B
Operating income	16.52%7.73B	15.14%3.58B	0.41%6.64B	-7.93%3.11B	4.49%6.61B	25.26%3.38B	26.49%6.32B	27.34%2.7B	10.89%5B	10.11%2.12B
Cost of sales	-8.46%-1.42B	-6.06%-691.06M	19.28%-1.31B	20.57%-651.59M	-22.32%-1.62B	-47.18%-820.36M	-22.91%-1.33B	-21.97%-557.37M	-20.01%-1.08B	-17.74%-456.98M
Operating expenses	-8.46%-1.42B	-6.06%-691.06M	19.28%-1.31B	20.57%-651.59M	-22.32%-1.62B	-47.18%-820.36M	-22.91%-1.33B	-21.97%-557.37M	-20.01%-1.08B	-17.74%-456.98M
Gross profit	18.50%6.31B	17.54%2.89B	6.83%5.32B	-3.88%2.46B	-0.25%4.98B	19.56%2.56B	27.47%5B	28.82%2.14B	8.62%3.92B	8.18%1.66B
Selling expenses	-16.07%-2.91B	-16.87%-1.35B	-6.56%-2.51B	7.36%-1.16B	1.93%-2.36B	-21.19%-1.25B	-17.97%-2.4B	-23.99%-1.03B	-29.70%-2.04B	-32.09%-830.18M
Administrative expenses	-13.14%-599.3M	-14.46%-264.19M	-6.09%-529.69M	10.36%-230.81M	-11.93%-499.28M	-36.60%-257.47M	-21.66%-446.08M	-15.29%-188.48M	10.89%-366.66M	15.50%-163.48M
Research and development expenses	-10.28%-1.56B	-11.71%-632.42M	9.33%-1.42B	27.04%-566.13M	9.56%-1.56B	-19.09%-775.89M	-21.99%-1.73B	-3.95%-651.54M	-24.06%-1.42B	-38.03%-626.8M
Impairment and provision	-57.37%2.92M	-145.32%-827K	689.16%6.84M	94.36%1.83M	-93.79%867K	-95.31%939K	188.27%13.97M	150.54%20.03M	---15.83M	---39.63M
-Other impairment is provision	-57.37%2.92M	-145.32%-827K	689.16%6.84M	94.36%1.83M	-93.79%867K	-95.31%939K	188.27%13.97M	150.54%20.03M	---15.83M	---39.63M
Special items of operating profit	966.20%319.51M	303.65%38.78M	-125.34%-36.89M	-100.94%-19.04M	-65.91%145.59M	905.89%2.03B	-68.71%427.08M	-145.53%-251.85M	208.84%1.36B	1,410.37%553.17M
Operating profit	85.95%1.56B	39.11%684.65M	17.52%836.49M	-78.70%492.16M	-17.29%711.8M	5,521.48%2.31B	-40.59%860.61M	-92.61%41.11M	56.29%1.45B	86.71%556.11M
Financing income	40.72%55.75M	4.47%26.55M	-27.91%39.62M	-17.86%25.41M	-8.20%54.96M	2.23%30.94M	-12.33%59.87M	8.02%30.26M	160.16%68.29M	158.17%28.01M
Financing cost	-37.73%-95.8M	-106.81%-48.54M	-101.22%-69.56M	-29.26%-23.47M	-0.47%-34.57M	1.93%-18.16M	51.43%-34.41M	60.94%-18.51M	47.02%-70.85M	40.44%-47.4M
Share of profits of associates	-66.42%-2.72M	-10,700.00%-1.91M	-128.03%-1.63M	102.27%18K	4,963.48%5.82M	-104.91%-793K	100.26%115K	97.38%-387K	-216.53%-43.92M	-238.85%-14.75M
Share of profit from joint venture company	-57.67%1.61M	202.79%1.74M	87.73%3.79M	-51.69%573K	2,594.67%2.02M	2,137.74%1.19M	127.78%75K	139.55%53K	31.30%-270K	-235.00%-134K
Earning before tax	87.25%1.51B	33.92%662.49M	9.28%808.72M	-78.72%494.69M	-16.50%740.04M	4,325.15%2.32B	-36.78%886.25M	-89.94%52.52M	74.12%1.4B	132.20%521.84M
Tax	-96.42%-170.32M	-54.56%-58.88M	-232.39%-86.71M	25.81%-38.09M	-164.45%-26.09M	-646.35%-51.35M	-58.32%40.48M	-71.57%9.4M	168.98%97.12M	182.85%33.06M
After-tax profit from continuing operations	86.15%1.34B	32.20%603.61M	1.13%722M	-79.91%456.6M	-22.96%713.95M	3,570.60%2.27B	-38.17%926.73M	-88.84%61.92M	125.64%1.5B	200.21%554.9M
Earning after tax	86.15%1.34B	32.20%603.61M	1.13%722M	-79.91%456.6M	-22.96%713.95M	3,570.60%2.27B	-38.17%926.73M	-88.84%61.92M	125.64%1.5B	200.21%554.9M
Minority profit	----	----	----	----	80.39%-811K	56.47%-811K	49.41%-4.14M	36.18%-1.86M	-55.80%-8.18M	-327.38%-2.92M
Profit attributable to shareholders	86.15%1.34B	32.20%603.61M	1.01%722M	-79.92%456.6M	-23.22%714.76M	3,464.66%2.27B	-38.23%930.87M	-88.57%63.78M	125.10%1.51B	200.68%557.81M
Basic earnings per share	86.21%0.54	38.89%0.25	7.41%0.29	-79.31%0.18	-25.00%0.27	4,250.00%0.87	-37.93%0.36	-90.48%0.02	107.14%0.58	162.50%0.21
Diluted earnings per share	86.21%0.54	38.89%0.25	7.41%0.29	-79.07%0.18	-25.00%0.27	4,200.00%0.86	-37.93%0.36	-90.48%0.02	107.14%0.58	162.50%0.21
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS
Audit Opinions	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--
Auditor	KPMG	--	KPMG	--	KPMG	--	KPMG	--	KPMG	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"